Trametinib DMSO solvate - CAS# 1187431-43-1 Catalog No.:M10955-10 Its primary mechanism is direct

Its primary mechanism is direct stimulation of β1 receptors of the sympathetic nervous system

Appl Biochem Biotechnol

1) and 5-HT-evoked increases in intracellular calcium (pIC50 = 10

preceded by desmosterol changes that would serve as a predictive safety biomarker for lenticular opacity

Smiles: CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl

Trametinib DMSO solvate - CAS# 1187431-43-1 Catalog No.:M10955-10 Its primary mechanism is directTrametinib, also known as GSK1120212, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in various cancer cell